Dapagliflozin, Cardio-Metabolic Risk Factors and Type-2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 186 participants.
Also called NCT03377335
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 186 participants
- Sponsor
- Registry
-
NCT03377335
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Italy
- Registry status
- Unknown status
Technical summary
Registry record NCT03377335. Randomized; no masking; primary purpose treatment. Start 2017-12-22 (actual); primary completion 2018-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dapagliflozin, Cardio-Metabolic Risk Factors and Type-2 Diabetes
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Dapagliflozin 10mg
- Intervention (Drug)
- Metformin
- Lead sponsor
- University of Palermo
- Collaborator
- AstraZeneca
- Collaborator
- University of Catania
Record details
- Record id
cardio:ct-nct03377335- Content hash
93c9cfa30660ce381960d4aefa59473c178befcb71059669465ea258d6792650